• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    ADC Shows ZYNLONTA Works With Antibodies In Large B-Cell Lymphoma

    PR NEWSWIRE

    ADC Therapeutics axes lead solid tumor drug after phase 1 blow

    FIERCE BIOTECH

    ADC Therapeutics Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics to Present at Upcoming Investor Conferences

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics Reports Q2 2024 Results And Operational Update

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics To Host Q2 2024 Results Call On August 6

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    ADC Therapeutics To Participate In Wainwright BioConnect Investor Conference

    GLOBENEWSWIRE

    ADC Therapeutics At RBC Healthcare Conference 2024

    GLOBENEWSWIRE

    ADC touts early Zynlonta results in marginal zone lymphoma

    FIERCE PHARMA

    ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma

    GLOBENEWSWIRE

    ADC Reports Q1 2024 Results, Provides Business Update

    GLOBENEWSWIRE

    ADC Prices $105M Common Shares, Pre-Funded Warrants Offering

    GLOBENEWSWIRE

    ADC Therapeutics Q1 2024 Call, Pipeline Update On May 6

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Thera Announces Updates on Trial ZYNLONTA with Glofitamab/Mosunetuzumab

    GLOBENEWSWIRE

    ADC Thera to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

    GLOBENEWSWIRE

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    GLOBENEWSWIRE

    ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Summit

    GLOBENEWSWIRE

    ADC Therapeutics Announces Abstracts Accepted for Presentation

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in TD Cowen 44th Annual Health Care Conference

    GLOBENEWSWIRE

    ADC Therapeutics Provides Business Updates

    GLOBENEWSWIRE

    ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

    GLOBENEWSWIRE

    ADC Tx, Aldeyra leave programs behind in 2023

    FIERCE BIOTECH

    ADC Therapeutics Announces Initial Results from Phase 2 Evaluating ZYNLONTA

    GLOBENEWSWIRE

    ADC Therapeutics Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    ADC Therapeutics Receives NYSE Notice of Non-Compliance With Listing Standards

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

    GLOBENEWSWIRE

    ADC Therapeutics Announces Abstracts Accepted for Presentation at ASH Meeting

    GLOBENEWSWIRE

    ADC Therapeutics to Host Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in September Investor Conferences

    GLOBENEWSWIRE

    ADC Therapeutics calls it quits on Adagene solid tumor collab

    FIERCE BIOTECH

    ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs

    GLOBENEWSWIRE

    ADC Therapeutics Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference

    GLOBENEWSWIRE

    Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA

    GLOBENEWSWIRE

    After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial

    FIERCE PHARMA

    ADC Therapeutics pauses enrollment in cancer drug trial after patient deaths

    REUTERS

    ADC Therapeutics Announces Evolution of Board of Directors

    GLOBENEWSWIRE

    ADC Announces LOTIS-2 Results Demonstrating Durable Responses of ZYNLONTA

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in the Jefferies Healthcare Conference

    GLOBENEWSWIRE

    ADC Therapeutics to Participate in the RBC Capital Markets Global Conference

    BUSINESSWIRE

    ADC implements `lower risk` strategy of layoffs, pipeline culls

    FIERCE BIOTECH

    ADC Therapeutics Reports1Q 2023 FYR and Provides Business and Strategy Update

    BUSINESSWIRE

    ADC Releases Annual Report on Form 20-F for the Fiscal Year Ended December

    BUSINESSWIRE

    ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

    BUSINESSWIRE

    ADC Therapeutics Reports Q4 and Full Year 2022 Financial Results

    BUSINESSWIRE

    ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results

    BUSINESSWIRE

    ADC Announces Pricing of Underwritten Offering by a Selling Shareholder

    BUSINESSWIRE

    ADC Therapeutics to Participate in February Investor Conferences

    BUSINESSWIRE

    ADC Therapeutics` Zynlonta (loncastuximab tesirine) Receives Approval in Europe

    EMA

    IntoCell Enters into Development and License Agreement with ADC Therapeutics

    PR NEWSWIRE

    ADC Therapeutics to Participate in 41st Annual J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.